TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24305660
Drug: Ginger patch
Normalized name: MENTHOL 2 g in 100 g / METHYL SALICYLATE 2 g in 100 g TOPICAL PATCH [Timing Pain Savior Fragrant Ginger Patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger patch
Study: 21423025
Drug: Extended daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended daily NVP (ExtNVP) through 14 weeks
Study: 21423025
Drug: Extended daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended daily NVP + ZDV (ExtNVP/ZDV) through 14 weeks
Study: 21423025
Drug: Control (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (single-dose nevirapine + 1-week zidovudine)
Study: 17563161
Drug: High post
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High post acute treatment levels of decentering and low cognitive reactivity
Study: 142248
Drug: Tilidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilidine (100 mg i.m.)
Study: 142248
Drug: Pethidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (100 mg i.m.)
Study: 26124508
Drug: Standard quitline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard quitline treatment
Study: 17186000
Drug: Buspirone 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 60 mg p.o. co-administered with morphine
Study: 17186000
Drug: Placebo co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo co-administered with morphine
Study: 25046070
Drug: Desloratadine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine (5 mg) plus montelukast (10 mg)
Study: 15347373
Drug: Desloratadine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine (5 mg) plus placebo
Study: 9772141
Drug: Cooked egg
Normalized name: egg shell, cooked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooked egg protein (25 g of cooked 13C- and 15N-labeled egg protein)
Study: 9772141
Drug: Raw egg
Normalized name: Egg, white, raw, fresh
DrugBank: Egg white (DB10528)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raw egg protein (25 g of raw egg protein)
Study: 1351
Drug: Visken (beta-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visken (beta-receptor blocking agent)
Study: 30887965
Drug: Single Bond
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Bond Universal dentin bonding agent
Study: 23644851
Drug: 7.2% hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.2% hypertonic saline - 6% hydroxyethyl starch (HS-HES) solution
Study: 19934563
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field therapy (PEMF) for 30 sessions (45 minutes each) at a frequency of 1 Hz and current intensity of 30 mili ampere.
Study: 19934563
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment for 30 sessions (45 minutes each).
Study: 11482341
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 2x 1 g daily
Study: 11482341
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) aiming at blood trough levels of 120-150 ng/ml
Study: 9591815
Drug: Fluocinonide 0.05%
Normalized name: FLUOCINONIDE 0.05% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocinonide 0.05% cream
Study: 31087132
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy including glucocorticoids and methotrexate
Study: 31087132
Drug: Refractory JDM
Normalized name: Glycerin 0.14 g in 7 g TOPICAL PATCH [Mefactory Piggy Peeling Pad]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refractory JDM treatments including azathioprine, ciclosporin, intravenous immune globulins, mycophenolate mofetil, and rituximab
Study: 31087132
Drug: Validated tools
Approvals — FDA: no, EMA: no, PMDA: no
Description: Validated tools for assessing disease activity, disease damage, and treatment responses
Study: 22653043
Drug: RenalGuard therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RenalGuard therapy (hydration with saline and NAC controlled by the RenalGuard System and furosemide)
Study: 22653043
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate solution and N‐acetylcysteine (NAC) (Control group)
Study: 22653043
Drug: RenalGuard therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RenalGuard therapy
Study: 17261422
Drug: Target hemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target hemoglobin level of 13 to 15 g/dL (group 1)
Study: 17261422
Drug: Target hemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target hemoglobin level of 10.5 to 11.5 g/dL (group 2)
Study: 15297194
Drug: Concurrent cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent cisplatin and radiotherapy (RT)
Study: 11260007
Drug: SDZ ASM
Normalized name: Asm-024 cation
DrugBank: Asm-024 cation (DB19385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDZ ASM 981 1% cream
Study: 11260007
Drug: Betamethasone‐17‐valerate 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone‐17‐valerate 0.1% cream
Study: 11260007
Drug: Vehicle of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle of SDZ ASM 981 1% cream
Study: 9558039
Drug: 4‐Methylpyrazole (4‐MP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐Methylpyrazole (4‐MP), 15 mg/kg body weight dissolved in 50 ml of orange juice
Study: 3243929
Drug: Tianeptine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianeptine (12.5 mg) administered after fasting
Study: 3243929
Drug: Tianeptine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianeptine (12.5 mg) administered after a standardized breakfast
Study: 28361616
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment plus standard medical therapy
Study: 21336108
Drug: Terlipressin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (1 mg over 30 mins followed by continuous infusion of 2 μg·kg(‐1)·h(‐1) for 48 hrs)
Study: 19858438
Drug: High social
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High social support treatment
Study: 19858438
Drug: Low social
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low social support treatment
Study: 15450119
Drug: 50 mcg
Normalized name: D3, 50 mcg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mcg vaginal misoprostol
Study: 10931388
Drug: Conventional immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunotherapy (IT)
Study: 8218956
Drug: Two products
Normalized name: Ceo-Two Rectal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two products with lower bioavailability
Study: 31574585
Drug: Relaxation intervention
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation intervention (RELAX; face‐to‐face classes and daily home practice of progressive muscle relaxation and mindfulness meditation)
Study: 20675978
Drug: CER 15
Normalized name: Acid Reducer 150mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: CER 15 mg
Study: 20675978
Drug: CER 30
Normalized name: CER-001
DrugBank: CER-001 (DB18538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CER 30 mg
Study: 20675978
Drug: CIR 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIR 10 mg
Study: 17405870
Drug: Assisted-control ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assisted-control ventilation plus volume guarantee (VG) (Vt = 5 ml/kg)
Study: 16292641
Drug: Glutamate (1
Normalized name: Glutamate (13-N)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamate (1 M, 0.2 ml) alone
Study: 9365148
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg preprandial
Study: 9365148
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg postprandial
Study: 9365148
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg postprandial
Study: 8466733
Drug: Slow-release isradipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release isradipine (SRO) 2.5 mg
Study: 8466733
Drug: Slow-release isradipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release isradipine (SRO) 5 mg
Study: 3959323
Drug: 1 liter
Normalized name: ISOPROPYL ALCOHOL 75 mL in 100 mL TOPICAL GEL [Hand Sanitizer Cristal Prime 1 liter]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 liter of 3% amino acid solution daily for 5 days postoperatively
Study: 3959323
Drug: Balanced 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced 5% glucose-containing electrolyte solutions
Study: 24375313
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control group (CTL)
Study: 22210078
Drug: Sutureless amniotic
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sutureless amniotic membrane patch with a modified symblepharon ring
Study: 22210078
Drug: Conventional sutured
Normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional sutured amniotic membrane patch
Study: 20537750
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro mix 25/75 (LM25)
Study: 18612876
Drug: Intravenous patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient‐controlled analgesia (PCA‐IV)
Study: 11878685
Drug: Nicorandil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (10 mg twice a day)
Study: 363480
Drug: Pindolol in
Normalized name: pindolol Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol in combination with classical antihypertensives
Study: 27991835
Drug: Stimulant medication
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant medication (lisdexamfetamine 30, 50, or 70 mg/day)
Study: 27991835
Drug: Stimulant medication
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant medication (lisdexamfetamine)
Study: 25403015
Drug: Acceptance-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance-based behavioral therapy (ABBT)
Study: 21041570
Drug: Warfarin anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin anticoagulation (target international normalized ratio, 2.0 to 3.0)
Study: 21041570
Drug: Dabigatran, 110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran, 110 mg twice daily (low dose)
Study: 21041570
Drug: Dabigatran, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran, 150 mg twice daily (high dose)
Study: 18835660
Drug: Clozapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (mean modal dose: 266.7±77.9mg)
Study: 15520691
Drug: Incremental bite
Normalized name: PAD,BITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental bite advancement using a Twin-block appliance with 2 mm initial advancement and subsequent 2 mm advancements at 6 weekly intervals.
Study: 7936222
Drug: Aspartame (approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (approximately 30 mg/kg/d)
Study: 2467138
Drug: Amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5 mg adjusted to 5.0 mg and to 10.0 mg o.d.)
Study: 2467138
Drug: Verapamil (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (80 mg b.i.d. titrating to 160 mg b.i.d.)
Study: 27571237
Drug: 35% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% hydrogen peroxide gel
Study: 30713266
Drug: 37% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37% carbamide peroxide gel
Study: 30713266
Drug: Non-thermal atmospheric
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-thermal atmospheric plasma treatment
Study: 18464882
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 900 mg/day
Study: 18464882
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 600 mg/day
Study: 11368289
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg/day plus estrogen
Study: 11368289
Drug: Risedronate 30
Normalized name: risedronate 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 30 mg/day
Study: 11368289
Drug: Risedronate 30
Normalized name: risedronate 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 30 mg/day for 2 months
Study: 8188018
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms Sulprostone gel
Study: 8188018
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg Gemeprost vaginal pessary
Study: 3276901
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (5-fluorouracil, semustine, and vincristine)
Study: 21276244
Drug: OROS-MPH (54
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS-MPH (54 mg/day for 8 weeks)
Study: 19455195
Drug: Early start
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early start dialysis (eGFR > 10 ml/min/1.73m²)
Study: 1588370
Drug: MFL (methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFL (methotrexate 250 mg/m2, fluorouracil 500 mg/m2, leucovorin rescue) for 12 courses
Study: 1588370
Drug: Expectancy (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectancy (no chemotherapy until symptoms appeared)
Study: 29747575
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing (MI) and cognitive behavioural therapy (CBT) skills training
Study: 17664468
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² and cisplatin 75 mg/m² plus fluorouracil 750 mg/m²/d continuous infusion (DCF)
Study: 17664468
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m² plus fluorouracil 1,000 mg/m²/d continuous infusion (CF)
Study: 16136167
Drug: 3+7+7 combination
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3+7+7 combination of daunorubicin, Ara‐C, and 6‐thioguanine (DAT)
Study: 16136167
Drug: High-dose Ara‐C
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Ara‐C during the second induction course
Study: 16136167
Drug: Intensive consolidation
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive consolidation chemotherapy
Study: 16136167
Drug: High-dose Ara‐C
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Ara‐C and multidrug resistance modulator cyclosporine
Study: 10426601
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone sodium phosphate (0.25 mg/kg)
Study: 6576814
Drug: Immunotherapy (I)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (I)
Study: 27132696
Drug: Methotrexate 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 3.5 g/m² on day 1 plus cytarabine 2 g/m² twice daily on days 2 and 3 (group A)
Study: 27132696
Drug: Methotrexate-cytarabine plus
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate-cytarabine plus rituximab 375 mg/m² on days -5 and 0 (group B)
Study: 27132696
Drug: Methotrexate-cytarabine-rituximab plus
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate-cytarabine-rituximab plus thiotepa 30 mg/m² on day 4 (group C)
Study: 24149580
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous remifentanil analgesia (20 mcg up to 60 mcg, lockout interval 1-2 minutes)
Study: 24149580
Drug: Patient-controlled epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled epidural analgesia (0.1% bupivacaine with 2 mcg/mL fentanyl, initiation bolus 15 mL; maintenance bolus 10 mL, lockout interval 20 minutes, basal infusion 5 mL/h)
Study: 20135168
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume (LTV, V(T) 7 ml/kg)
Study: 20135168
Drug: Traditional tidal
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional tidal volume (TTV, V(T) 10 ml/kg)
Study: 11919241
Drug: Cisplatin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (50 mg/m²), ifosfamide (5 g/m² over 24 hours), and mesna (6 g/m² during ifosfamide infusion and the following 12 hours)
Study: 11919241
Drug: Bleomycin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin (30 units over 24 hours on day 1) followed by cisplatin (50 mg/m²), ifosfamide (5 g/m² over 24 hours), and mesna (6 g/m² during ifosfamide infusion and the following 12 hours)
Study: 8522468
Drug: Trovafloxacin 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin 30 mg
Study: 8522468
Drug: Trovafloxacin 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin 300 mg
Study: 8522468
Drug: Trovafloxacin 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin 600 mg
Study: 8522468
Drug: Trovafloxacin 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin 1000 mg
Study: 2022159
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ranitidine (0.2 mg/kg/hr)
Study: 2022159
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of ranitidine (50 mg every 4 hr)
Study: 26293575
Drug: Budesonide/formoterol 320/9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 320/9 μg (twice daily)
Study: 26293575
Drug: Formoterol 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 9 μg (twice daily)
Study: 26293575
Drug: Reliever salbutamol
Normalized name: LidoPro Pain Relieving Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reliever salbutamol 90 μg
Study: 21893941
Drug: low-dose GH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose GH therapy (0.033 mg/kg/day) for 2 years
Study: 21893941
Drug: high-dose GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose GH therapy (0.100 mg/kg/day) for 1 year
Study: 21893941
Drug: mid-dose GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: mid-dose GH therapy (0.067 mg/kg/day) for 1 year
Study: 21893941
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (all doses)
Study: 17185207
Drug: Peer counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer counseling + Contingency contracting (PC + CC)
Study: 9836525
Drug: Nocturnal hypoglycemia
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nocturnal hypoglycemia (48 +/- 2 mg/dl)
Study: 9836525
Drug: Nocturnal euglycemia
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nocturnal euglycemia (109 +/- 1 mg/dl)
Study: 8020526
Drug: iomeprol 350
Normalized name: Iomeprol 350 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: iomeprol 350 mgI/ml
Study: 8020526
Drug: iopromide 370
Normalized name: IOPROMIDE 370mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopromide 370 mgI/ml
Study: 31929980
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg/bid
Study: 31929980
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard dosage of esomeprazole)
Study: 27681944
Drug: dalotuzumab 10
Normalized name: DALOTUZUMAB
DrugBank: Dalotuzumab (DB11840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dalotuzumab 10 mg/kg once weekly (arm A)
Study: 27681944
Drug: dalotuzumab 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: dalotuzumab 7.5 mg/kg every second week (arm B)
Study: 19508464
Drug: atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 20 mg/day
Study: 19508464
Drug: atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 40 mg/day
Study: 18056233
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation with adjunctive psychiatric rehabilitation
Study: 9740915
Drug: Topical nasal
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nasal steroids
Study: 8049498
Drug: Sulofenur (LY186641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulofenur (LY186641) given orally daily x 21 schedule
Study: 8049498
Drug: Sulofenur (LY186641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulofenur (LY186641) given orally daily x 5 for 3 weeks schedule
Study: 2924255
Drug: Intensive maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive maintenance therapy with 6-mercaptopurine and methotrexate, plus vincristine and prednisone pulses (treatment 1)
Study: 2924255
Drug: Less intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less intensive maintenance therapy with 6-mercaptopurine and methotrexate, plus vincristine and prednisone pulses (treatment 2)
Study: 28715503
Drug: Aspirin continuation
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin continuation (100 mg/day until operative day)